Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 832 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Plaque Clear all
Completed Not applicable Interventional Results available

Evaluating the Effect of Tooth Cleaning Devices on Oral Health

NCT01250769
View directory record Official record
Conditions
Dental Plaque
Interventions
Manual Toothbrush, Interproximal Cleaning Device
Device
Lead sponsor
Philips Oral Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Evaluating the Efficacy of a Gum Health Formulation on Teeth Whitening in Patients With Gingivitis and Periodontitis

NCT02906982
View directory record Official record
Conditions
Tooth Discoloration, Periodontal Diseases
Interventions
Gum health formulation in intra-oral device, Gum health formulation on toothbrush
Other
Lead sponsor
Glo Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

NCT00617994
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Fridley, Minnesota • Rochester, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Quality and Amyloid-Beta Kinetics

NCT03077620
View directory record Official record
Conditions
Amyloid-beta
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00292396
View directory record Official record
Conditions
Psoriasis
Interventions
Anti IL-12 monoclonal antibody/ABT-874, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis

NCT00990561
View directory record Official record
Conditions
Stable Plaque Psoriasis
Interventions
Ultravate ointment twice daily + LacHydrin lotion twice daily, Ultravate ointment once daily + LacHydrin lotion twice daily
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

NCT02749370
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jul 22, 2026, 4:09 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

NCT01680588
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]NAV4694
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
7
States / cities
New Haven, Connecticut • Chicago, Illinois • Elk Grove Village, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab low dose, secukinumab high dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 22, 2026, 4:09 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00605059
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I]AV94
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study

NCT03364270
View directory record Official record
Conditions
Carotid Arteries
Interventions
PET/CT Imaging with [F-18] RGD-K5
Drug
Lead sponsor
Balaji Tamarappoo
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Effect of Evolocumab on Coronary Plaque Characteristics

NCT04710368
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Evolocumab Injections
Drug
Lead sponsor
Annapoorna Kini
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.

NCT02309723
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Beta amyloid imaging
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580
View directory record Official record
Conditions
Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
MSB11022, Humira®
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction

NCT02063217
View directory record Official record
Conditions
Amyloid-beta
Interventions
Sodium Oxybate, Sleep deprivation
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Identification of Adverse Plaque Characteristics by Coronary MR Angiography

NCT01986868
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary MR Angiography (CMRA)
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 22, 2026, 4:09 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

NCT00657813
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-330 as a brain SPECT tracer of Beta-Amyloid
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 3 Interventional

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT04175613
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 22, 2026, 4:09 PM EDT
Not listed Phase 1Phase 2 Interventional

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

NCT01670513
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Low Strength, IDP-118 High Strength
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Santa Rosa, California • Clinton Township, Michigan • Fort Gratiot, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Jul 22, 2026, 4:09 PM EDT
Recruiting Not applicable Interventional

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

NCT05879913
View directory record Official record
Conditions
Prostate Cancer
Interventions
Coronary CT Angiography (CCTA)
Device
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT04607980
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ABP 654, Ustekinumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 2 Interventional

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

NCT00192517
View directory record Official record
Conditions
Psoriasis
Interventions
MEDI-522, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
18
States / cities
Little Rock, Arkansas • Fresno, California • Vallejo, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

NCT04718896
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cypress, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 4:09 PM EDT